Ligand-based drug design combines AI and QSAR modeling to prioritize drug candidates, minimizing preclinical failures and ...
Nuclera and leadXpro Partner to Accelerate Structure-Based Drug Design for Complex Membrane Proteins
CAMBRIDGE, England & BOSTON & VILLIGEN, Switzerland--(BUSINESS WIRE)--Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based ...
In drug discovery, virtual screening is a fast and cost-effective way of narrowing down vast chemical libraries to identify the most promising hits, reducing synthesis and testing requirements while ...
This process is costly, time-consuming, and has a low success rate. KAIST researchers have developed an AI model that, using only information about the target protein, can design optimal drug ...
Thomas D. Grant, PhD, assistant professor of structural biology, has been awarded the Chancellor’s Horizon Award for Faculty ...
Understanding drug resistance is crucial. Quantum modeling offers insights into molecular interactions, enhancing drug ...
Structure Therapeutics Inc. has announced the selection of its lead oral small molecule amylin receptor agonist, ACCG-2671, which shows promising preclinical results including potent target engagement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results